Vir Biotechnology

$62.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.48 (-2.31%) Today

+$0.12 (+0.19%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VIR and other stocks, options, and ETFs commission-free!

About VIR

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA. The listed name for VIR is Vir Biotechnology, Inc. Common Stock.

CEO

George A. Scangos

Employees

229

Headquarters

San Francisco, California

Founded

2016

Market Cap

7.95B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.12M

High Today

$63.84

Low Today

$56.75

Open Price

$60.93

Volume

952.71K

52 Week High

$141.01

52 Week Low

$25.31

Analyst Ratings

86%

of 7 ratings

Buy

86%

Hold

Sell

14%

VIR Earnings

-$4.60

-$3.07

-$1.53

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.70 per share

Actual

-$0.83 per share